Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24878496 | 0.89 | CYP19A1 (0.39) | CYP19A1POLBMIFMEN1KMT2A | |
| SCHEMBL22854013 | 0.87 | CYP19A1 (0.39) | CYP19A1POLBMIFMEN1KMT2A | |
| SCHEMBL22854014 | 0.85 | CYP19A1 (0.38) | CYP19A1POLBMIFMEN1KMT2A | |
| SCHEMBL24878497 | 0.82 | CYP19A1 (0.36) | CYP19A1POLBMIFMEN1KMT2A | |
| SCHEMBL19986373 | 0.79 | CYP19A1 (0.40) | CYP19A1POLBMAPK14 | |
| SCHEMBL5998647 | 0.79 | NOTUM (0.41) | CYP19A1MAPK14 | |
| SCHEMBL23974498 | 0.75 | MIF (0.42) | MIFHDAC1 | |
| SCHEMBL21152290 | 0.74 | CYP19A1 (0.39) | CYP19A1POLBMIFMEN1KMT2A | |
| SCHEMBL23978348 | 0.73 | EPHX2 (0.43) | CYP19A1HDAC1 | |
| SCHEMBL13878325 | 0.73 | CYP19A1 (0.51) | CYP19A1POLBMIFMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009076-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009076-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, CYP2C19, CYP3A7 | CYP19A1 276/4885POLB 718/4885MIF 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.